BioSpace News Archive

For 20 years, Kibow Biotech has been refining a novel approach to maintaining healthy kidney function “Enteric Dialysis”. Enteric Dialysis utilizes probiotics (yes, probiotics) to metabolize the waste products (toxins) building up in the bloodstream due to reduced kidney function.

Following the successful completion of its Phase 2 trial, the Company is making plans to advance the clinical development of Brilacidin-IBD.

AMPAC Fine Chemicals (AFC) is pleased to announce the addition of two new members to their executive team.

Almac Clinical Technologies, a global leader in technology-enabled solutions for managing clinical trial patient and supplies data, has extended the functionality of its industry-leading IXRS 3 IRT platform to include Accountability and Reconciliation Tracking (ART).

Irvine-based Biogennix announced today that it is expanding its distribution efforts for its novel bone graft substitutes, Morpheus and osteoSPAN to full national distribution.

Wilson Therapeutics (publ) today announced that the discussions with the FDA and the EMA, regarding the study protocol for the single pivotal Phase 3 FOCuS trial for WTX101 in Wilson Disease, have been concluded successfully.

Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has appointed Philip Payne as Chief Commercial Officer, to support the group’s continued growth.

BONE THERAPEUTICS today announces that it will participate in the following upcoming key investor and partnering conferences in the fourth quarter of 2017: Bio-Europe.

Illumina, Inc. today announced its financial results for the third quarter of fiscal year 2017.

amfAR, The Foundation for AIDS Research, announced on Monday the 2017 recipients of the Mathilde Krim Fellowships in Basic Biomedical Research. Named in honor of amfAR Founding Chairman Dr. Mathilde Krim, the Krim Fellowship program supports bright young scientists seeking innovative solutions to HIV/AIDS.